The addition of chemotherapy to lung cancer surgery is now considered as the standard of care. Solid data support postoperative chemotherapy but only few results are available in the preoperative setting. To define which timing of perioperative chemotherapy offers the best survival improvement, the IFCT 0002 study is conducted in France.

Further study details as provided by Intergroupe Francophone de Cancerologie Thoracique:

Primary Outcome Measures:

Compare 3-Years survival [ Time Frame: 3 years ]

Secondary Outcome Measures:

Compare Objective response rate [ Time Frame: 6 weeks ]

Enrollment:

530

Study Start Date:

May 2001

Estimated Study Completion Date:

December 2008

Detailed Description:

In this multicenter study, patients are randomized to receive either two preoperative chemotherapy cycles plus two additional preoperative cycles if they respond to chemotherapy, or two preoperative plus two postoperative cycles in case of response.

Eligibility

Ages Eligible for Study:

18 Years to 75 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Histologically or cytologically NSCLC stade I or II Resectable disease WHO performance status of 2 or less

Exclusion Criteria:

NSCLC stage III or IV

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00198354

Locations

France

CHU Besancon - Pneumologie

Besancon, France, 25000

Sponsors and Collaborators

Intergroupe Francophone de Cancerologie Thoracique

Eli Lilly and Company

Bristol-Myers Squibb

Investigators

Principal Investigator:

Alain Depierre, Pr

IFCT

More Information

No publications provided by Intergroupe Francophone de Cancerologie Thoracique